Trial Profile
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Ciforadenant (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Corvus Pharmaceuticals
- 28 Jul 2021 Status changed from recruiting to completed.
- 31 May 2020 Results (n=82) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 29 May 2020 According to a Corvus Pharmaceuticals media release, from this study were presented at the ASCO20 Virtual Scientific Program.